Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

The US-developed NOVAVAX vaccine against COVID-19 has been approved Monday by the European Medicines Agency (EMA), thus becoming the fifth drug of its kind to become available at a continental level.

Novavax takes the RNA sequence that codes ... vaccine that covers the needs of the space as it is now. The vaccine is approved in over 40 countries and recommended by the WHO.

These awards were approved by the Compensation C Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will ...

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.

Novavax also earned global approvals for and commercialized its first vaccine ever for COVID-19, ramping up quickly to meet the demands of the global pandemic. Dr. Young helped to guide the ...

The Novavax's COVID vaccine was approved by the US Food and Drug Administration for people age 12 and older in August 2024. This places it alongside Moderna's and Pfizer-BioNTech's refreshed formulas.